Analyser av Nanexa

Nanexa: Clinical milestones align ahead of phase Ib/II and licensing push - Emergers

Nanexa continues to strengthen the foundation for the upcoming Phase Ib/II study in the NEX-22 project, with preliminary PK data from the fi...

Emergers • 07 May 09:23

Nanexa: Targeting treatment of first patient in phase Ib/II with NEX-22 before year-end - Emergers

Nanexa’s Q4 report did not reveal much new, although the conference call provided welcome clarity on the rationale behind the extension of p...

Emergers • 20 Feb 09:41

Nanexa: Financing secured into 2026 to drive NEX-22 development - Emergers

With the directed issue of units amounting to SEK 35m, supplemented by SEK 20m in loans, Nanexa secures funding for its continued developmen...

Emergers • 27 Jan 10:35

Nanexa: Phase I results position NEX-22 for licensing opportunities and a head start in long-acting GLP-1 - Emergers

The positive results in Nanexa’s Phase I study for NEX-22, a once-monthly depot formulation of the GLP-1 analog liraglutide for type 2 diabe...

Emergers • 29 Nov 2024 10:50

Nanexa: Progress for rival at Novo illustrates the significant value potential in Nanexa - Emergers

NEX-22 is progressing as expected, with the last patient in Phase I treated, results anticipated later in November, and Phase IIb scheduled ...

Emergers • 08 Nov 2024 10:34

Nanexa: NEX-22 Progress, Revaluation and Financing - Emergers

After initiating dosing of the first patient in June with Nanexa’s long-acting depot formulation of the GLP-1 analog liraglutide, NEX-22 for...

Emergers • 28 Aug 2024 09:36

Nanexa Q1 2024: Insightful capital markets day - Redeye

Redeye updates its view of Nanexa following the Q1 report and recent events in the company, including the CMD earlier this week, which offer...

Redeye • 10 May 2024 10:01

Nanexa: Insights from CMD underscore near- to mid-term opportunities with significant potential - Emergers

Apart from a slight further delay in the start of Phase I with NEX-22, the report for Q1’24 proved rather uneventful.

Emergers • 10 May 2024 09:38

Nanexa: Short Q1 comment - Redeye

Redeye notes that Nanexa’s Q1 report offered no material surprises, with revenues at SEK7.

Redeye • 03 May 2024 11:19

Nanexa Q1 report: work in progress - ABG

Muted quarter with work in progress NEX-22 Ph 1 approval and start exp.

ABG Sundal Collier • 03 May 2024 10:03

Nanexa: NEX-22, partner projects, and Novo Nordisk evaluation prioritized - Redeye

Redeye updates its view of Nanexa following the Q4 report and recent events in the company.

Redeye • 22 Feb 2024 09:16

Nanexa: Focus on dual GLP-1 opportunities and the partner projects - Emergers

Apart from a write down of capitalized development related to the suspended projects NEX-18 and NEX-20, there was not much new in Nanexa’s f...

Emergers • 22 Feb 2024 08:40

Nanexa: Q4 report: Update on NEX-22 Ph 1 - ABG

NEX-22 start potentially delayed into Q2'24e (Q1'24e) Next milestone: NEX-22 Ph 1 approval Webcast today at 11:30 CET Relevant events durin...

ABG Sundal Collier • 21 Feb 2024 09:02

Nanexa: Lining up to make Nanexa (close to) a pure GLP-1 play - Emergers

Following the focusing of the roadmap after the rights issue in October, Nanexa has now announced a further streamlining of its activities t...

Emergers • 21 Dec 2023 08:07

Nanexa: Focused approach into 2024 - Redeye

Redeye comments on the news that Nanexa has decided to focus its business on three key areas, which, combined with cost savings, will extend...

Redeye • 20 Dec 2023 12:43

Nanexa: Focus on NEX-22, Novo Nordisk and partner projects - ABG

Short/medium term priorities: NEX-22, Novo and partner projects NEX-18 and NEX-20 on hold NEX-22 Ph 1 CTA assessed by EMA; Ph 1 start in Q1'...

ABG Sundal Collier • 20 Dec 2023 09:03

Nanexa: Signs evaluation agreement regarding a monoclonal antibody - Redeye

Redeye endorses today’s news that Nanexa has signed an evaluation agreement with a global pharma company regarding using Pharmashell to deve...

Redeye • 29 Nov 2023 10:51

Nanexa: New evaluation agreement in mAb space - ABG

Signs evaluation agreement with "large global pharma company" To evaluate PharmaShell in depot formulation of monoclonal antibody Not a new ...

ABG Sundal Collier • 29 Nov 2023 09:09

Nanexa Q3: Focused approach - Redeye

Redeye updates its view of Nanexa following the Q3 report and recent events in the company.

Redeye • 21 Nov 2023 11:02

Nanexa: Raising our LOAs following a review of the projects - Emergers

With the dust settling after the recent rights issue, Nanexa now progresses with its more focused roadmap, concentrating on Phase I trials w...

Emergers • 21 Nov 2023 08:07

Nanexa: Q3 report: NEX-22 on focus - ABG

No material updates in Q3 report Next material milestone: NEX-22 Ph 1 study in type 2 diabetes Webcast today at 15:00 CET Relevant events d...

ABG Sundal Collier • 20 Nov 2023 09:12

Nanexa: Valuation update after the rights issue - ABG

SEK 75m from rights issue leads to project re-prioritisation Primary focus on GLP-1 RA space (NEX-22 & Novo Nordisk collab.

ABG Sundal Collier • 07 Nov 2023 07:15

Nanexa: Outcome of rights issue forces an investor-friendly focus on core projects - Emergers

With a subscription rate of 34.7% of the rights issue, and a utilization of guarantee commitments corresponding to 27.

Emergers • 01 Nov 2023 12:18

Nanexa: Outcome of rights issue announced - Redeye

Redeye comments on the outcome of Nanexa’s rights issue, that resulted in a subscription rate of 34.

Redeye • 31 Oct 2023 14:54

Nanexa: Comment on preliminary key financials for Q3 and impressions from investor meeting - Redeye

Redeye comments on Nanexa’s preliminary key financial information for Q3.

Redeye • 12 Oct 2023 07:34

Nanexa: Variable roadmap with emphasis on NEX-22 and potential Novo Nordisk deal - Emergers

With the recently completed Phase 1 study for NEX-20 yielding positive results, and the widespread global interest in GLP-1, Nanexa now has ...

Emergers • 11 Oct 2023 08:24

Nanexa: Takeaways from investor meeting - ABG

Provides updated development plan at investor meeting Detailed path forward for different rights issue outcomes NEX-22: CTA submission in Q4...

ABG Sundal Collier • 10 Oct 2023 09:12

Nanexa: NEX-20 Ph 1 study completed - ABG

NEX-20 Ph 1 study in multiple myeloma completed Mild to moderate local skin reactions; new formulation under development Investor meeting ne...

ABG Sundal Collier • 06 Oct 2023 09:14

Nanexa: Clinical phase I trial with NEX-20 completed - Redeye

Redeye is encouraged by the announcement that Nanexa’s clinical phase I trial with NEX-20 (NEX-20-01), a long-acting formulation of lenalido...

Redeye • 05 Oct 2023 15:59

Nanexa: Update on capital raise - ABG

Rights issue of SEK 121m; subscription period: 12-26 Oct Use of proceeds could finance operations well into '25 67% dilution; new fair value...

ABG Sundal Collier • 02 Oct 2023 08:34

Nanexa: Capital raise to pursue a broad set of opportunities in 2024 and 2025 - Emergers

As we had expected, Nanexa announced a SEK 121m rights issue, albeit at a slightly higher than expected both discount and amount.

Emergers • 22 Sep 2023 08:01

Nanexa: Announces rights issue - Redeye

Redeye comments on Nanexa’s rights issue that was announced earlier today.

Redeye • 21 Sep 2023 16:01

Nanexa: Focusing on the right things - ABG

We provide a fresh look at Nanexa's prospects GLP-1 receptor agonists a good space to focus efforts Updated valuation with new fair value ra...

ABG Sundal Collier • 12 Sep 2023 09:04

Nanexa Q2: Solid progress but a capital injection is on the horizon - Redeye

Redeye comments on Nanexa’s Q2 2023 report and endorses the company’s recent progress related to NEX-20 and NEX-22.

Redeye • 24 Aug 2023 09:24

Nanexa Q2: Solid progress but a capital injection is on the horizon - Redeye

Redeye comments on Nanexa’s Q2 2023 report and endorses the company’s recent progress related to NEX-20 and NEX-22.

Redeye • 24 Aug 2023 09:24

Nanexa: Progress with NEX-20 and NEX-22 Amid Rising GLP-1 Interest - Emergers

Nanexa’s Q2’23 advancements with NEX-20 and NEX-22 underscore the company’s forward momentum.

Emergers • 24 Aug 2023 08:29

Nanexa Q2: Solid progress but a capital injection is on the horizon - Redeye

Redeye comments on Nanexa’s Q2 2023 report and endorses the company’s recent progress related to NEX-20 and NEX-22.

Redeye • 24 Aug 2023 07:29

Nanexa Q2 report: Advancing according to plan - ABG

Outlook focus on NEX-22 with Ph1 start in early '24e Positive initial NEX-20 Ph1 PK reported yesterday Live commentary today at 11:00 CET R...

ABG Sundal Collier • 23 Aug 2023 09:08

Nanexa: Positive first human NEX-20 PK results - ABG

PK data for NEX-20 confirms slow-release of lenalidomide Results in line with preclinical studies Nanexa will report Q2 tomorrow at 08:00 CE...

ABG Sundal Collier • 22 Aug 2023 12:48

Nanexa: Initial clinical phase I results of NEX-20 - Redeye

Redeye endorses the positive results from Nanexa’s clinical phase I trial with NEX-20, a long-acting formulation of lenalidomide.

Redeye • 22 Aug 2023 10:15

Nanexa: Moments of truth closing in - Redeye

Redeye reviews the Nanexa case in light of the recent development of NEX-20, its latest project NEX-22, and its collaboration with Novo Nord...

Redeye • 22 May 2023 08:16

Nanexa: Solid progress in development into 2023, with funding needs on the horizon - Emergers

After positive pre-clinical results in rats with NEX-22 (for treatment of type 2 diabetes) in Q1, we now see results from phase I for NEX-20...

Emergers • 05 May 2023 08:57

Nanexa: Q1 report - ABG

No material updates in the Q1 report NEX-20 Ph 1 study completed by June '23e Live commentary today at 15:00 CET Events during the quarter ...

ABG Sundal Collier • 04 May 2023 09:57

Nanexa Q1: Brief comment on the report - Redeye

Redeye comments on Nanexa’s Q1 report and notes important key activities carried out in the quarter.

Redeye • 04 May 2023 09:41

Nanexa Q4 2022: A Stronger Case - Redeye

Redeye return with a research update following the Q4 report and recent progress in the company.

Redeye • 17 Feb 2023 11:10

Nanexa: Validation from Novo Nordisk positions Nanexa for an eventful year ahead - Emergers

After a news packed Q4 2022, including an exclusivity and evaluation agreement with Novo Nordisk, start of Phase I with NEX-20 and two addit...

Emergers • 17 Feb 2023 09:02

Nanexa: Q4'22 report - ABG

Neutral reaction expected to uneventful report NEX-20 in the clinic, no news on NEX-18 timelines Live commentary today at 14:00 CET A quart...

ABG Sundal Collier • 16 Feb 2023 10:49

Nanexa: Evaluation Agreement Novo Nordisk - Redeye

Redeye is impressed and relieved by yesterday’s news that Nanexa has signed an exclusivity- and evaluation agreement with Novo Nordisk worth...

Redeye • 22 Dec 2022 15:04

Nanexa: Settlement Reached With Vitrivax - Redeye

Redeye has a mildly positive take on today’s news that Nanexa has reached a settlement with Vitrivax.

Redeye • 16 Nov 2022 15:58

Nanexa: Our Q3 Comment - Redeye

Redeye comments on Nanexa’s Q3 report and our view the of progress in the quarter.

Redeye • 26 Oct 2022 09:40

Nanexa Q3 report: back to the clinic soon - ABG

Encouraging progress on BD, litigation, and clinical front Opens for making NEX-18 superior to Vidaza Co.

ABG Sundal Collier • 25 Oct 2022 10:04

Nanexa: Update in Patent Infringement Case - Redeye

Redeye is cautiously optimistic about today’s update from Nanexa’s patent infringement case, indicating that the parties (Nanexa and Vitriva...

Redeye • 27 Sep 2022 15:58

Nanexa: NEX-22 Will Target Liraglutide - Redeye

Redeye gives a short comment on Nanexa’s new project: NEX-22.

Redeye • 16 Sep 2022 16:08

Nanexa announces NEX-22 project - ABG

NEX-22: Liraglutide for type 2 diabetes (T2D) Liraglutide (Novo’s Victoza) DKK 15bn in 2021 Preclinical studies ongoing, clinical trial ex...

ABG Sundal Collier • 15 Sep 2022 09:53

Nanexa: Signs Evaluation Agreement with Licensing Option - Redeye

Redeye endorses today’s news that Nanexa has signed an evaluation agreement with a global pharmaceutical company, that also includes an opti...

Redeye • 30 Aug 2022 13:54

Nanexa: Our Q2 Comment - Redeye

Redeye comments on the Q2 report from Nanexa, which came in more or less as expected.

Redeye • 29 Aug 2022 09:50

Nanexa: Q2 report - ABG

New facility receives GMP certification Developed first formulations with mAbs Neutral share price reaction expected today New facility GMP ...

ABG Sundal Collier • 26 Aug 2022 09:13

Nanexa: Getting ready for its comeback - ABG

New pilot plant lays foundation for licensing agreements NEX-18 programme pause pushes approvals to ‘28 Updated valuation with new fair val...

ABG Sundal Collier • 27 Jul 2022 08:53

Nanexa: Extends Agreement with Applied Materials - Redeye

Redeye gives a short comment on today’s news and reiterate our view of Nanexa.

Redeye • 21 Jul 2022 18:28

Nanexa: PharmaShell patent granted by EPO - ABG

Covers manufacturing method and resulting products Good timing with recent completion of new plant Raises appeal of PharmaShell for potenti...

ABG Sundal Collier • 28 Apr 2022 15:00

Nanexa: Our Q1 Comment - Redeye

Redeye comments on Nanexa’s Q1 report and give our view of progress so far in 2022.

Redeye • 20 Apr 2022 15:28

Nanexa: Progress in Patent Infringement Litigation - Redeye

We give a short comment on the progress in Nanexa's patent infringement case.

Redeye • 18 Mar 2022 12:37

Nanexa: Our Q4 Comment - Redeye

Redeye comments on Nanexa's Q4 report and summarize our view of progress in 2021.

Redeye • 18 Feb 2022 07:48

Nanexa: A Path Forward for NEX-18 - Redeye

Redeye comments on today’s update on the NEX-18 clinical program.

Redeye • 11 Feb 2022 07:55

Nanexa: Short Comment on Sensor Coating Order - Redeye

We give a brief comment on today’s news that Nanexa has received orders worth in total SEK 1.

Redeye • 03 Sep 2021 13:21

Nanexa: Our Q2 comments - Redeye

Redeye maintains its view of Nanexa and base case of SEK 9.

Redeye • 20 Aug 2021 14:21

Nanexa: Q2’21 Report - ABG

Important events during and after the quarter Important events during the quarter included the start of the first-in-human Ph I trial of NEX...

ABG/Introduce • 20 Aug 2021 09:23

Nanexa: Our Comment on the Completed Rights Issue - Redeye

We adjust our base case of Nanexa following the company’s completed rights issue.

Redeye • 08 Jul 2021 12:32